The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Advice for physicians managing patients with ET: personalizing therapeutic approaches
In this video, Alexander Coltoff, MD, Medical University of South Carolina, Charleston, SC, offers guidance to physicians managing patients with essential thrombocythemia (ET), highlighting the importance of adopting an individualized approach that considers each patient’s unique needs and priorities. These may include reducing thrombotic risk, mitigating disease transformation, or managing symptoms. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I think one of the reasons that I like treating people with MPNs, and I think a lot of my colleagues here do too, is that MPNs really deserve an individualized approach more so than other types of cancer, right? So for a new ET patient, that could be someone who’s 30 years old and has a very low risk of thrombosis, but maybe is at a higher risk of transformation, versus an 85-year-old patient who was just diagnosed, who was very asymptomatic and just needs a little bit of thrombosis risk reduction...
Yeah, I think one of the reasons that I like treating people with MPNs, and I think a lot of my colleagues here do too, is that MPNs really deserve an individualized approach more so than other types of cancer, right? So for a new ET patient, that could be someone who’s 30 years old and has a very low risk of thrombosis, but maybe is at a higher risk of transformation, versus an 85-year-old patient who was just diagnosed, who was very asymptomatic and just needs a little bit of thrombosis risk reduction. So I think the most important thing for physicians seeing new patients is to figure out what’s most important to that patient. Is it mitigating thrombotic risk? Is it mitigating the risk of disease transformation? Is it helping symptoms? And tailoring treatment based on that. So some treatments we know are better at reducing symptom burden, but maybe less apt at reducing platelet numbers and vice versa. And as we continue to have more therapies, I think we’ll have even more kind of refined and nuanced discussions in that space.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Speaking fees: Incyte, Blueprint Medicines, Sobi; Advisory Boards: PharmaEssentia, Blueprint Medicines.
